Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94224ArticlesСтатьиResearch ArticleProspects for personalized utilization of non-vitamin K anticoagulants based on the assessment of pharmacokinetics in patients with atrial fibrillationПерспективы персонализации применения новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий на основе оценки фармакокинетикиKryukovA. VКрюковАлександр Валерьевич

аспирант каф. клинической фармакологии и терапии ГБОУ ДПО РМАПО

SychevD. AСычевДмитрий Алексеевич

д-р мед. наук, проф., зав. каф. клинической фармакологии и терапии ГБОУ ДПО РМАПО

dimasychev@mail.ruSavelevaM. IСавельеваМарина Ивановна

д-р мед. наук, проф. каф. клинической фармакологии и терапии ГБОУ ДПО РМАПО, вед. науч. сотр. группы клинико-фармакологических технологий НИЦ ГБОУ ДПО РМАПО

RyabovaA. VРябоваАнастасия Владиславовна

науч. сотр. группы клинико-фармакологических технологий НИЦ ГБОУ ДПО РМАПО

IlinaE. SИльинаЕкатерина Сергеевна

науч. сотр. группы клинико-фармакологических технологий НИЦ ГБОУ ДПО РМАПО

YurovskyA. YuЮровскийАртем Юрьевич

науч. сотр. группы клинико-фармакологических технологий НИЦ ГБОУ ДПО РМАПО

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian FederationГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России15012015171VOL 17, NO1 (2015)ТОМ 17, №1 (2015)414328122021Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94224

The article is devoted to the actual problem of non-vitamin K anticoagulants application (NOAC) for secondary stroke prevention in patients with atrial fibrillation. Therapeutic drug monitoring is considered a promising tool for personalized anticoagulation that allows to prevent the development of complications associated with NOAC administration.

Статья посвящена актуальной проблеме применения новых оральных антикоагулянтов (НОАК) у пациентов с фибрилляцией предсердий для вто-ричной профилактики инсульта. Терапевтический лекарственный мониторинг рассматривается как перспективный инструмент персонализацииантикоагулянтной терапии, позволяющий предотвратить развитие осложнений, связанных с приемом НОАК.

atrial fibrillationsecondary prevention of ischemic strokenon-vitamin K anticoagulantstherapeutic drug monitoringфибрилляция предсердийвторичная профилактика ишемического инсультановые оральные антикоагулянтытерапевтиче- ский лекарственный мониторингStewart S, Hart C.L, Hole D.J, Mc Murray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.Go A.S, Hylek E.M, Phillips K.A et al. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.Miyasaka Y, Barnes M.E, Gersh B.J et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.Heeringa J, Van der Kuip D.A, Hofman A et al. Prevalence, incidence and life time risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.Naccarelli G.V, Varker H, Lin J, Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-9.Lloyd-Jones D.M, Wang T.J, Leip E.P et al. Life time risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042-6.Wolf P.A, Abbott R.D, Kannel W.B. A trial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.Murtagh B, Smalling R.W. Cardioembolic stroke. Curr Atherosclr Rep 2006; 8: 310-6.Mac Dougall N.J.J, Amarasinghe S, Muir K.W. Secondary prevention of stroke. Expert Rev Neurother 2009; 7: 1103-15.Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in - hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. Cerebrovasc Dis 1998; 8: 8-13.Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6: 150-61.Hart R.G, Pearce L.A, Aguilar M.I. Meta - analysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.Atrial Fibrillation Investigators. Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (published correction appears in Arch Intern Med 1994; 154: 2254). Arch Intern Med 1994; 154: 1449-57.Guidelines for the management of atrial fibrillation. ESC 2012.Practical guide on the use of new oral anticoagulants in patients with non - valvular atrial fibrillation. EHRA 2013.Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ 2012.Shibazaki K, Kimura K, Aoki J et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331 (1-2): 90-3.Doll D.N, Barr T.L, Simpkins J.W. Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. Aging Disease 2014; 5 (5): 294-306.House R.V, Descotes J. Cytokines in human health immunotoxicology, pathology, and therapeutic applications. 2007.Cohen D. Dabigatran: how the drug company withheld important analyses. 2014.Samama M.M, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130 (Suppl. 1): s88-9.Mani H, Herth N, Kasper A. Point - of - care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (5): 624-31.Delavenne X, Moracchini J, Laporte S et al. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal 2012; 58: 152-6.Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35 (5): 515-24.